Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
Approximately 20.9% of participants on the highest 12 mg dose reported this symptom
Unintended muscle loss, which often accompanies rapid weight loss, is another common concernand another reason why protein products are flying off shelves
Mechanotransduction for Muscle Protein Synthesis via Mechanically Activated Ion Channels
However, its not considered safe to become pregnant while taking the medication
Key timing considerations: Morning injection produces peak appetite suppression around mid-afternoon to evening, ideal for those who struggle with afternoon snacking and dinner portions Evening injection produces peak levels overnight and through the morning, beneficial for those who overeat at breakfast or need better fasting glucose control The 13-hour half-life means effects noticeably diminish in the latter half of each 24-hour cycle Consistency is absolutely critical with daily dosing because missed doses create more significant gaps in drug levels Many liraglutide users tie their injection to a specific daily habit (brushing teeth, morning coffee ritual) to prevent missed doses Dulaglutide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 24 to 72 hours after injection Recommended timing approach: Similar pharmacokinetic profile to tirzepatide in terms of half-life, though the mechanism is pure GLP-1 agonism
